Leica Microsystems - The Wise Choice for Theranostic Partnering

Products by Leica Microsystems


Selection of HER2 over-expressing tumor populations by immunohistochemistry using the Leica Oracle™ HER2 Bond™ IHC System developed by Leica Microsystems
Leica Microsystems offers a unique array of expertise that not only enhances the commercial success of your drug but also assists in advancing critical decisions in the drug development process.

In partnership with your individual program’s needs, Leica Microsystems will collaborate with you to develop the most accurate, reliable and robust theranostic system for your targeted therapy.

We provide the following: